WO2001023366A3 - Vasopressin antagonist and diuretic combination - Google Patents

Vasopressin antagonist and diuretic combination Download PDF

Info

Publication number
WO2001023366A3
WO2001023366A3 PCT/US2000/026370 US0026370W WO0123366A3 WO 2001023366 A3 WO2001023366 A3 WO 2001023366A3 US 0026370 W US0026370 W US 0026370W WO 0123366 A3 WO0123366 A3 WO 0123366A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
vasopressin antagonist
diuretic
diuretic combination
methods
Prior art date
Application number
PCT/US2000/026370
Other languages
French (fr)
Other versions
WO2001023366A2 (en
Inventor
Grosse Evelyn Jane Ellis
Gayle Penniman Orczyk
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Priority to AU76151/00A priority Critical patent/AU7615100A/en
Publication of WO2001023366A2 publication Critical patent/WO2001023366A2/en
Publication of WO2001023366A3 publication Critical patent/WO2001023366A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention provides methods of increasing urine flow in humans while minimizing the loss of electrolytes or ions, the methods comprising administering to a human in need thereof a combination of N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide (or a pharmaceutically acceptable salt thereof), also known as VPA-985, and one or more diuretic agents, as well as pharmaceutical compositions and kits or packages for such combinations.
PCT/US2000/026370 1999-09-27 2000-09-26 Vasopressin antagonist and diuretic combination WO2001023366A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76151/00A AU7615100A (en) 1999-09-27 2000-09-26 Vasopressin antagonist and diuretic combination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40665899A 1999-09-27 1999-09-27
US09/406,658 1999-09-27

Publications (2)

Publication Number Publication Date
WO2001023366A2 WO2001023366A2 (en) 2001-04-05
WO2001023366A3 true WO2001023366A3 (en) 2001-06-07

Family

ID=23608937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026370 WO2001023366A2 (en) 1999-09-27 2000-09-26 Vasopressin antagonist and diuretic combination

Country Status (3)

Country Link
AR (1) AR030916A1 (en)
AU (1) AU7615100A (en)
WO (1) WO2001023366A2 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAN P.S. ET AL: "VPA - 985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, (1998) 449/- (439-443)., XP000991018 *
SWAN, S. K. (1) ET AL: "Interaction between VPA - 985, an ADH (V2) antagonist, and furosemide.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (SEPT., 1999) VOL. 10, NO. PROGRAM AND ABSTR. ISSUE, PP. 124A. MEETING INFO.: 32ND ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY MIAMI BEACH, FLORIDA, USA NOVEMBER 1-8, 1999 AMERICAN SOCIETY OF NE, XP000989912 *
TAYLOR S.H.: "Refocus on diuretics in the treatment of heart failure.", EUROPEAN HEART JOURNAL, (1995) 16/SUPPL. F (7-15)., XP000991592 *

Also Published As

Publication number Publication date
WO2001023366A2 (en) 2001-04-05
AU7615100A (en) 2001-04-30
AR030916A1 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
CA2244785A1 (en) Pentafluorobenzenesulfonamides and analogs
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
WO2001042219A3 (en) Novel substituted phenanthridinones and methods of use thereof
IL140622A0 (en) Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
TR199802698T2 (en) Solid oral dose forms of valsartan.
EP1741713A3 (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2002076979A8 (en) 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
WO2003024955A3 (en) Small molecule inhibitors of caspases
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
AU3850600A (en) Dalda analogs and their use
ATE272628T1 (en) SUBSTITUTED GAMMA-PHENYL-DELTA-LACTONES AND ANALOGUES THEREOF, AND USES THEREOF
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
CA2325739A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
EP1195166A3 (en) Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension
WO2000039083A3 (en) Pyrazole compounds and uses thereof
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU6440600A (en) Combination of active agents, said combination containing clonidine
HUP0103431A3 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
BR9914156A (en) Formulation of 2-methyl-thieno-benzodiazepine
WO1996028185A3 (en) Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP